Warning letters, 483s, Recalls, Import Alerts, Audit observations
USFDA issued a Warning letter to Intas, Matoda, Ahmedabad facility on 21 November 2023. This
SCYNEXIS recalled 2 lots of Brexafemme (ibrexafungerp) tablets in U.S. due to potential cross contamination
SCYNEXIS issued the recall of 2 lots of BREXAFEMME (ibrexafungerp tablets) due to Potential for
Florida based VistaPharm LLC is recalling in US one lot of ulcer treatment drug Sucralfate
Centaur India formulation facility at Pune, Maharashtra, India was issued Warning letter by FDA citing
Strides recalled 2700 bottles of Losartan Potassium USP 25 mg tablets in US for presence
Warning letter / Centrient India / MARCS-CMS 640196/ 320-23-06/ DECEMBER 07, 2022/ Observation 2 USFDA
In September 2022, USFDA issued a Warning letter to Lupin API facility at Tarapur, India
USFDA Warning letter to Mylan in 2020 cited inadequacy of cleaning, cleaning procedures, risk assessment of
